The combination of Tumor Targeted Superantigens (TTS) and Taxotere significantly improved anti-tumor activity compared to the respective mono therapy. Furthermore, combining TTS and Taxotere synergistically prolonged long-term survival in tumor bearing mice.
In conclusion, the results of the study demonstrate that TTS therapy is suitable for combination treatment agents such as Taxotere, and suggest a significant potential for such a combination in human cancer therapy.
The drug candidate Anyara, using the TTS technology, is currently in pivotal Phase II/III clinical trials for renal cell cancer and an interim analysis is planned for mid 2008.